How Agenus' Pipeline Progress Unlock Its Next Growth Phase
AGEN advances BOT/BAL into phase III for MSS colorectal cancer as survival data and global access efforts shape its next growth phase.
Agenus: Weighing The Clinical Progress Against The Company's Cash
Agenus: Weighing The Clinical Progress Against The Company's Cash
AGEN Stock Dips 19.4% in a Month: Time to Buy, Hold or Sell?
Agenus' shares slide after weak Q1 results, but BOT/BAL phase III progress, survival data and Zydus backing keep long-term growth hopes alive.
Agenus (AGEN) Q1 Earnings and Revenues Miss Estimates
Agenus (AGEN) came out with quarterly earnings of $1.02 per share, missing the Zacks Consensus Estimate of $2.1 per share. This compares to a loss of $1.03 per share a year ago.
Is Agenus (AGEN) Stock Outpacing Its Medical Peers This Year?
Here is how Agenus (AGEN) and Align Technology (ALGN) have performed compared to their sector so far this year.
Agenus (AGEN) Earnings Expected to Grow: What to Know Ahead of Q1 Release
Agenus (AGEN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Bio-Techne's Q3 Earnings on Deck: What's in Store for the Stock?
TECH gears up for Q3 results with modest revenue growth expected as biotech funding trends and product momentum shape the outlook.
Here's How Henry Schein Is Placed Ahead of Q1 Earnings
HSIC heads into Q1 earnings results with steady estimates, a 5.1% revenue growth outlook and strength across distribution, specialty products and tech.
Is Agenus (AGEN) Outperforming Other Medical Stocks This Year?
Here is how Agenus (AGEN) and Apyx Medical (APYX) have performed compared to their sector so far this year.
Agenus (AGEN) is a Great Momentum Stock: Should You Buy?
Does Agenus (AGEN) have what it takes to be a top stock pick for momentum investors? Let's find out.
Can Agenus (AGEN) Run Higher on Rising Earnings Estimates?
Agenus (AGEN) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
All You Need to Know About Agenus (AGEN) Rating Upgrade to Strong Buy
Agenus (AGEN) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
